
Description: Recombinant blood products have developed for many years in foreign countries, but China's blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources are the key to the development of Chinese blood product enterprises. Amid the industrial prosperity and favorable policies, China had more than 190 plasma collection stations with the production-use plasma volume of 4,700 tons and the total lot release volume jumped by 3.36 million bottles year on year to 55.76 million bottles in 2015.

Given stringent requirements on new domestic plasma stations, Shanghai RAAS, China Biologic Products (Shandong Taibang and Guizhou Taibang), Hualan Biological Engineering, Tiantan Biological (including Chengdu Rongsheng) and Yuanda Shuyang which boast abundant capital, powerful R&D strength and rich plasma station resources have become the top five companies in China blood product industry, contributing 61.9% to China's production-use plasma volume in 2015.

From the point of view of the product structure, human albumin is still the largest type of blood products in China, but its supply has slowed down with a lower contribution 58.8% to China's total blood product lot release volume in 2015. In recent years, the rising lot release volume of Chinese human albumin is mainly attributed to ample supply of imported products. In 2011-2015, the lot release volume of human albumin imported by China grew at a CAGR of 23.7%, accounting for as much as 55.6% of the total. China's top four human albumin import enterprises - Behring, Baxter, Grifols and Octapharma seized 50.7% of the total lot release volume in 2015.

China's second largest type of blood products - human immunoglobulin (pH4) for intravenous injection saw its lot release volume jump by 31.5% year on year to 9.4 million bottles (2.5g / bottle) and its share increase to 16.9% in 2015. Over the same period, tetanus human immunoglobulin, hepatitis B immune globulin and other immune globulin products and coagulation factor products witnessed growth in lot release volume except human rabies immunoglobulin whose lot release volume declined slightly.

The research and development of human blood coagulation factor VIII, human prothrombin complex and other small products in rigid demand has made the most remarkable progress in recent years. Concerning human blood coagulation factor VIII, Shanghai Xinxiang had been approved to launched its human blood coagulation factor VIII, Shenzhen Weiguang had entered the new drug registration stage, Guangdong Shuanglin Bio-Pharmacy had embarked on trial production, Jiangxi Boya Bio-Pharmaceutical had gone into clinical phase III (the industrialization is expected in H2 2016), Wuhan Zhongyuan Ruide had obtained clinical approval and Harbin Pacific Biopharmaceutical had applied for clinical approval by the end of 2015.

In order to possess and effectively use plasma raw materials, enterprises are more willing to cooperate mutually in addition to acquisition. In August 2015, China Biologic Products and Xinjiang Deyuan signed a strategic cooperation agreement, under which the former should purchase at least 120/180/200 tons of plasma from the latter per year in the next three years. In 2015, Hebei Da'an Pharmaceutical and Guangdong Weilun actively planned to cooperate on the allocation of plasma fraction II + III, namely the former (it only produces human albumin now) should allocate partial plasma fraction II + III to Guangdong Weilun for the production of immunoglobulin products.

China Blood Product Industry Report, 2016-2019 focuses on the followings:

- Market characteristics, operating environments, status quo, etc. of China blood product industry;
- Supply and demand, competition pattern, import and export, development forecast, etc. of China blood product industry;
- Supply and demand, competition pattern, etc. of 8 blood product segments, including human albumin, human immunoglobulin (pH4) for intravenous injection, blood coagulation factor and tetanus human immunoglobulin;
- Operation, blood product business and prospects of 13 major Chinese blood product companies.
Contents:

1. Overview of Blood Product Industry
   1.1 Definition
   1.2 Classification
   1.3 Recombinant Blood Products
   1.4 Industry Chain
   1.5 Features

2. Overview of China Blood Product Industry
   2.1 Market Size
   2.2 Status Quo
   2.3 Supply and Demand
      2.3.1 Supply
      2.3.2 Demand
   2.4 Competition
   2.5 Operating Environment
      2.5.1 International
      2.5.2 Policy
      2.5.3 Domestic Biopharmaceutical Market
   2.6 Import and Export

3. Blood Product Market Segments in China
   3.1 Human Albumin
      3.1.1 Supply and Demand
      3.1.2 Competition Pattern
      3.1.3 Prospects
   3.2 Human Immunoglobulin (pH4) for Intravenous Injection
      3.2.1 Supply and Demand
      3.2.2 Competition Pattern
   3.3 Blood Coagulation Factor VIII
      3.3.1 Supply and Demand
      3.3.2 Competition Pattern
      3.3.3 Prospects
   3.4 Hepatitis B Immunoglobulin
      3.4.1 Supply and Demand
      3.4.2 Competition Pattern
   3.5 Human Immunoglobulin
      3.5.1 Supply and Demand
      3.5.2 Competition Pattern
   3.6 Human Prothrombin Complex
      3.6.1 Supply and Demand
      3.6.2 Competition Pattern
   3.7 Tetanus Immunoglobulin
      3.7.1 Supply and Demand
      3.7.2 Competition Pattern
   3.8 Human Rabies Immunoglobulin
      3.8.1 Supply and Demand
      3.8.2 Competition Pattern

4. Major Chinese Manufacturers
   4.1 China Biologic Products Inc.
      4.1.1 Profile
      4.1.2 Operation
      4.1.3 Revenue Structure
      4.1.4 Customers and Suppliers
      4.1.5 R&D and Investment
   4.1.6 Shandong Taibang Biological Products Co., Ltd.
   4.1.7 Guizhou Taibang Biological Products Co., Ltd.
   4.1.8 Xi’an Huitian Blood Products Co., Ltd.
   4.1.9 Outlook and Prospects
   4.2 Hualan Biological Engineering Inc.
      4.2.1 Profile
      4.2.2 Operation
      4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 Customers and Suppliers
4.2.6 R&D and Investment
4.2.7 Blood Products
4.2.8 Outlook and Prospects
4.3 Shanghai RAAS Blood Products Co., Ltd.
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 Customers and Suppliers
4.3.6 R&D and Investment
4.3.7 Blood Products
4.3.8 Outlook and Prospects
4.4 Beijing Tiantan Biological Products Co., Ltd.
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 Customers and Suppliers
4.4.6 R&D and Investment
4.4.7 Blood Products (Chengdu Rongsheng Pharmaceutical Co., Ltd.)
4.4.8 Outlook and Prospects
4.5 Zhenxing Biopharmaceutical and Chemical Co., Ltd.
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure
4.5.4 Gross Margin
4.5.5 Customers and Suppliers
4.5.6 R&D and Investment
4.5.7 Blood Products (Guangdong Shuanglin Bio-Pharmacy Co., Ltd.)
4.5.8 Outlook and Prospects
4.6 Jiangxi Boya Bio-Pharmaceutical Co., Ltd.
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 Customers and Suppliers
4.6.6 R&D and Investment
4.6.7 Blood Products
4.6.8 Outlook and Prospects
4.7 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
4.7.1 Profile
4.7.2 Blood Products
4.8 Shanghai Institute of Biological Products Co., Ltd.
4.8.1 Profile
4.8.2 Blood Products
4.9 Shanxi Kangbao Biological Product Co., Ltd.
4.9.1 Profile
4.9.2 Blood Products
4.10 Green Cross
4.10.1 Profile
4.10.2 Blood Products
4.11 Humanwell Healthcare Group Co., Ltd.
4.11.1 Profile
4.11.2 Operation
4.11.3 Blood Products (Wuhan Zhongyuan Ruide Biological Product Co., Ltd.)
4.12 Walvax Biotechnology Co, Ltd.
4.12.1 Profile
4.12.2 Operation
4.12.3 Blood Products (Hebei Da'an Pharmaceutical Co., Ltd. and Guangdong Weilun Biological Pharmaceutical Co., Ltd.)
4.13 Shenzhen Weiguang Biological Products Co., Ltd.
4.13.1 Profile
4.13.2 Operation
4.13.3 Revenue Structure
4.13.4 Gross Margin
4.13.5 Customers and Suppliers
4.13.6 R&D and Investment
4.13.7 Outlook and Prospects

5. Summary and Forecast
5.1 Company Analysis
5.2 Growth Prediction

List of Charts
- Basic Components of Blood
- Plasma Protein Separation Procedure
- Classification and Function of Blood Products
- Comparison between Gene Recombinant Blood Products and Traditional Blood Products
- Comparison between Domestic and Foreign Recombinant Blood Products in Types
- Blood Product Industry Chain
- Time Consumption of Plasma Collection and Separation Process
- Comparison between Blood Product Enterprises and Chemical & Pharmaceutical Enterprises in Operating Costs and Expenses
- Prices of Some Blood Products in China, 2014
- Lot Release Volume of Blood Products in China (by Product), 2009-2015
- Blood Product Structure in China (by Lot Release Volume), 2009-2015
- Per Capita Frequency of Plasma Donation and Plasma Collection in China vs. the Occident
- Plasma Collections in China vs. USA
- Production-use Plasma Volume in China, 2008-2015
- Number of Plasma Collection Stations in China, 2008-2015
- Geographical Distribution of Plasma Station Resources in China by the End of 2015
- Mainstream Blood Products with Medical Insurance Coverage in China
- Per Capita Consumption of Blood Products in China vs. Developed Countries
- Plasma Station Distribution, Production-use Plasma Volume and Blood Product Revenue of Major Blood Product Enterprises in China, 2014
- Plasma Station Distribution, Production-use Plasma Volume and Blood Product Revenue of Major Blood Product Enterprises in China, 2015
- Comparison of Chinese Blood Product Manufacturing Enterprises in Product Line
- Competition Pattern of Global Blood Product Enterprises, 2013
- Product Structure of Global Blood Products
- Blood Products Available in Overseas Market
- Global Blood Product Manufacturers
- Main Policies on Chinese Blood Products
- Average Human Albumin Purchase Price of Sample Hospitals in China, 2005-2014
- Proportion of Domestic and Imported Human Albumin in China (by Lot Release Volume), 2007-2015
- Market Share of Major Human Albumin Manufacturers in China (by Lot Release Volume), 2008-2015
- Consumption of Human Immunoglobulin (pH4) for Intravenous Injection per 1,000 Persons by Country, 2013 (g/1,000 persons)
- Lot Release Volume and Growth Rate of Human Immunoglobulin (pH4) for Intravenous Injection in China, 2007-2015
- Price of Human Immunoglobulin (pH4) for Intravenous Injection in China vs. Other Countries
- Average Purchase Price of Human Immunoglobulin (pH4) for Intravenous Injection of Sample Hospitals in China, 2005-2014
- Market Share of Major Manufacturers of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Lot Release Volume), 2007-2015
- Comparison between Human Blood Coagulation Factor VIII and Recombinant Blood Coagulation Factor VIII
- Per Capita Consumption of Recombinant VIII Factor and Plasma VIII Factor in Major Countries (IU/Person)
- Lot Release Volume and Growth Rate of Hepatitis B Immunoglobulin in China, 2009-2015
- Market Share of Major Hepatitis B Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-
2015
- Prices of Human Immunoglobulin in China by Dosage, 2014
- Lot Release Volume and Growth Rate of Human Immunoglobulin in China, 2008-2015
- Market Share of Major Human Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2015
- Lot Release Volume and Growth Rate of Human Prothrombin Complex in China, 2008-2015
- Market Share of Major Human Prothrombin Complex Manufacturers in China (by Lot Release Volume), 2008-2015
- Lot Release Volume and Growth Rate of Tetanus Immunoglobulin in China, 2008-2015
- Market Share of Major Tetanus Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2015
- Rabies Incidents and Death Rate in China, 2008-2014
- Equity Structure of China Biologic Products by the End of 2014
- Distribution of Blood Products Manufacturing Bases and Plasma Stations of CBPO, 2015
- Revenue and Operating Income of CBPO, 2008-2015
- Gross Margin of CBPO, 2011-2015
- Revenue Breakdown of CBPO (by Product), 2011-2015
- Revenue Structure of CBPO (by Product), 2010-2015
- CBPO’s Revenue from Top 5 Customers and % of Total Revenue, 2008-2014
- R&D Costs and % of Total Revenue of CBPO, 2010-2015
- Revenue and Operating Income of CBPO, 2014-2019E
- Revenue and Operating Income of Hualan Biological Engineering Inc., 2008-2015
- Revenue of Hualan Biological Engineering Inc. (by Sector), 2008-2015
- Gross Margin of Hualan Biological Engineering Inc. (by Product), 2008-2015
- Hualan Biological Engineering Inc.’s Revenue from Top 5 Customers and % of Total Revenue, 2007-2014
- Hualan Biological Engineering Inc.’s Procurement from Top 5 Suppliers and % of Total Procurement, 2007-2014
- Name List and Procurement Contribution of Hualan Biological Engineering Inc.’s Top 5 Suppliers, 2014
- R&D Costs and % of Total Revenue of Hualan Biological Engineering Inc., 2008-2015
- Types and Specifications of Blood Products of Hualan Biological Engineering Inc.
- Distribution of Plasma Collection Stations of Hualan Biological Engineering Inc. by the End of 2015
- Revenue and Gross Margin of Blood Products of Hualan Biological Engineering Inc. (by Product), 2008-2015
- Shanghai RAAS’s Subsidiaries and Their Operation, H1 2015 (RMB mln)
- Distribution of Plasma Stations of Shanghai RAAS by the End of 2015
- Revenue and Operating Income of Shanghai RAAS, 2008-2015
- Operating Revenue of Shanghai RAAS (by Product), 2008-2015
- Revenue of Shanghai RAAS (by Region), 2008-2015
- Gross Margin of Shanghai RAAS (by Product), 2008-2015
- Shanghai RAAS’s Revenue from Top 5 Customers and % of Total Revenue, 2008-2015
- Shanghai RAAS’s Procurement from Top 5 Suppliers and % of Total Procurement, 2007-2014
- R&D Costs and % of Total Revenue of Shanghai RAAS, 2008-2015
- Revenue and Operating Income of Shanghai RAAS, 2014-2019E
- TIANMABIO’s Subsidiaries and Their Revenue and Income, H1 2015 (RMB mln)
- Revenue and Operating Income of TIANMABIO, 2008-2015
- Revenue of TIANMABIO (by Sector), 2008-2015
- Revenue of TIANMABIO (by Region), 2008-2015
- TIANMABIO’s Procurement from Top 5 Suppliers and % of Total Procurement, 2008-2014
- TIANMABIO’s Revenue from Top 5 Customers and % of Total Revenue, 2008-2014
- Gross Margin of TIANMABIO (by Sector), 2008-2015
- R&D Costs and % of Total Revenue of TIANMABIO, 2009-2015
- Distribution of Plasma Collection Stations of TIANMABIO by the End of 2015
- Revenue and Gross Margin of Blood Products of TIANMABIO, 2008-2015
- Revenue and Operating Income of TIANTANBIO, 2014-2019E
- Revenue and Operating Income of Zhenxing Biopharmaceutical and Chemical, 2008-2015
- Operating Revenue of Zhenxing Biopharmaceutical and Chemical (by Product), 2009-2015
- Gross Margin of Zhenxing Biopharmaceutical and Chemical (by Product), 2009-2013
- Zhenxing Biopharmaceutical and Chemical's Revenue from Top 5 Customers and % of Total Revenue, 2009-2014
- Name List and Revenue Contribution of Zhenxing Biopharmaceutical and Chemical's Top 5 Customers, 2014
- Zhenxing Biopharmaceutical and Chemical's Procurement from Top 5 Suppliers and % of Total Procurement, 2014
- R&D Costs and % of Total Revenue of Zhenxing Biopharmaceutical and Chemical, 2009-2015
- Production-use Plasma Volume of Shuanglin Bio-Pharmacy, 2010-2015
- Distribution of Plasma Collection Stations of Shuanglin Bio-Pharmacy by the End of 2015
- Revenue and Gross Margin of Blood Products of Zhenxing Biopharmaceutical and Chemical, 2009-2015
- Revenue and Operating Income of Zhenxing Biopharmaceutical and Chemical, 2014-2019E
- Distribution of Single Plasma Collection Stations of Jiangxi Boya Bio-Pharmaceutical by the End of 2015
- Revenue of Jiangxi Boya Bio-Pharmaceutical (by Product), 2009-2015
- Operating Revenue of Jiangxi Boya Bio-Pharmaceutical (by Region), 2009-2014
- Jiangxi Boya Bio-Pharmaceutical's Revenue from Top 5 Customers and % of Total Revenue, 2009-2015
- Jiangxi Boya Bio-Pharmaceutical's Procurement from Top 5 Suppliers and % of Total Procurement, 2009-2015
- R&D Costs and % of Total Revenue of Jiangxi Boya Bio-Pharmaceutical, 2009-2015
- Products under Research and Progress of Jiangxi Boya Bio-Pharmaceutical as of Oct. 2015
- Distribution of Plasma Stations of Sichuan Yuanda Shuyang Pharmaceutical by the End of 2015
- Distribution of Plasma Stations of Shanghai Institute of Biological Products by the End of 2015
- Distribution of Plasma Stations of Shanxi Kangbao Biological Product by the End of 2015
- Distribution of Plasma Stations of Green Cross China by the End of 2015
- Revenue and Operating Income of Humanwell Healthcare, 2009-2015
- Production Industry Layout of Walvax Biotechnology
- Revenue and Operating Income of Walvax Biotechnology, 2009-2015
- Revenue of Walvax Biotechnology (by Product), 2009-2015
- Distribution of Single Plasma Collection Stations of Shenzhen Weiguang Biological Products by the End of 2015
- Plasma Collection Volume and Production-use Plasma Volume of Shenzhen Weiguang Biological Products, 2012-2015
- Revenue and Operating Income of Shenzhen Weiguang Biological Products, 2012-2015
- Capacity, Production and Sales Volume of Shenzhen Weiguang Biological Products (by Product), 2012-2015
- Revenue Breakdown of Shenzhen Weiguang Biological Products (by Product), 2012-2015 (RMB mln)
- Revenue Structure of Shenzhen Weiguang Biological Products (by Product), 2012-2015 (RMB mln)
- Gross Margin of Shenzhen Weiguang Biological Products (by Product), 2012-2015
- Name List and Revenue Contribution of Shenzhen Weiguang Biological Products' Top 5 Customers, 2012-2015
- Name List and Procurement Contribution of Shenzhen Weiguang Biological Products' Top 5 Suppliers, 2012-2015
- R&D Costs and % of Total Revenue of Shenzhen Weiguang Biological Products, 2012-2015
- Some Products under Research and Progress of Shenzhen Weiguang Biological Products by the End of 2015
- Fundraising Projects of Shenzhen Weiguang Biological Products
- Revenue and Operating Income of Shenzhen Weiguang Biological Products, 2014-2019E
- Number of Plasma Stations of Major Blood Product Enterprises in China as of Dec. 2015
Ordering:

Order Online - [http://www.researchandmarkets.com/reports/3627370/](http://www.researchandmarkets.com/reports/3627370/)

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Web Address: http://www.researchandmarkets.com/reports/3627370/
Office Code: SCBRAGNB

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 2650</td>
</tr>
<tr>
<td>Hard Copy:</td>
<td>USD 2800 + USD 58 Shipping/Handling</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 4000</td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [Mr] [Mrs] [Dr] [Miss] [Ms] [Prof]
First Name: __________________________ Last Name: __________________________
Email Address: * __________________________
Job Title: __________________________
Organisation: __________________________
Address: __________________________
City: __________________________
Postal / Zip Code: __________________________
Country: __________________________
Phone Number: __________________________
Fax Number: __________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: __________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World